Alzheon Moves Forward With Tramiprosate Development in Select Alzheimer’s Patients

Alzheon Moves Forward With Tramiprosate Development in Select Alzheimer’s Patients
Data from Phase 3 trials of tramiprosate (ALZ-801) suggest that the therapy might be modifying the disease course in patients with mild Alzheimer’s disease and two copies of the APOE4 gene, the drug’s developer, Alzheon, recently announced. With data in hand, the Framingham, Massachusetts, company plans to further clinical development of the compound. But for

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *